IPC Appoints New President for 2023
The IPC Board of Directors is pleased to announce that it has named Hervé Bachelez, MD, PhD, as its newly appointed President, effective January 1, 2023.
Thursday, January 26, 2023
Psoriasis News
THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results
Focus on Psoriasis: A Report from the 2022 IPC Think Tank – Miami
Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank scientific symposium was held on Friday, December 9th, in Miami, Florida. Read the full report or a summary of the five psoriasis focused sessions.
Tuesday, January 24, 2023
Meet Our 2022 Volunteers of the Year
The IPC’s global network of experts generously volunteers their time every year to educate and train other physicians to better care for people with psoriasis. We would like to recognize our top three Councilors that went above and beyond in 2022 to support our work.
Friday, January 20, 2023
Prioritizing the Patient Perspective in Psoriasis Care and Communications
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Wednesday, January 18, 2023
Nuevos Avances e Indicaciones en Psoriasis Pediátrica
La investigación de la Dra. Kelly Cordoro sobre la psoriasis pediátrica muestra que puede ser hora de repensar nuestras expectativas sobre las comorbilidades y el tratamiento.
Thursday, January 12, 2023
Novos Avanços e Direções na Psoríase Pediátrica
A pesquisa da Dra. Kelly Cordoro sobre psoríase pediátrica mostra que talvez seja hora de repensar nossas expectativas sobre comorbidades e tratamento.
Thursday, January 12, 2023
New Developments in Pediatric Psoriasis — And How to Help Parents Understand Them
Dr. Kelly Cordoro’s research on pediatric psoriasis shows it may be time to rethink our expectations about comorbidities and treatment.
Thursday, January 12, 2023
A Year in Review: Advancements in Psoriasis Care, Research, and Treatment
In 2022, the IPC advanced in the worldwide psoriasis community, ranging from multiple research efforts, education of dermatologists, and public awareness, reaching the patient communities. In addition to face-to-face events, the IPC has expanded its digital presence. Read some of IPC’s significant achievements from the past year and leave a comment letting us know what topics you want to see on the IPC website in the coming year!
Monday, January 9, 2023
Por Qué un Nuevo Sistema de Clasificación de la Gravedad de la Psoriasis Beneficiará más a los Pacientes de Psoriasis
El Proyecto de Reclasificación de la Severidad de la Psoriasis de los Consejos Internacionales de Psoriasis tiene como objetivo cambiar la clasificación de la gravedad de la psoriasis. La red de líderes de opinión clave del IPC acordó una definición para cada categoría de gravedad de la enfermedad.
Tuesday, December 27, 2022
Porque um Novo Sistema de Classificação de Gravidade da Doença Psoríase Atenderá Melhor os Pacientes com Psoríase
O Projeto de Reclassificação da Gravidade da Psoríase do Conselho Internacional de Psoríase visa alterar a classificação da gravidade da psoríase. A rede de líderes de opinião do IPC concordou com uma definição para cada categoria de gravidade da doença.
Tuesday, December 27, 2022
Why a New Psoriasis Disease Severity Classification System Will Better Serve Psoriasis Patients
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion leaders agreed on a definition for each category of disease severity.
Tuesday, December 27, 2022
European Commission Approves SPEVIGO® (spesolimab) for Generalized Pustular Psoriasis (GPP) Flares
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose. This decision builds on existing approvals in the United States and Japan.
Tuesday, December 20, 2022
Subscribe to the IPC Newsletter
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
